Monoclonal antibodies are big business. According to a report published by Deloitte, global sales of just the top 10 monoclonal antibodies amounted to $3.6 billion in 2009. That report asserted that "monoclonal antibodies (mAbs) have become one of the most valuable and rapidly growing segments of the worldwide pharmaceutical industry." Read More
